Gestational diabetes mellitus (GDM) is a critical yet under-recognized health challenge affecting approximately one in five pregnancies in the UK. Despite its prevalence and significant health risks for both mother and child, GDM remains substantially underdiagnosed due to flaws in current testing protocols.
Recent research reveals that standard NHS testing methods miss over 50% of GDM cases, exposing thousands of pregnant women to untreated risks that could otherwise be mitigated with timely diagnosis and care.
The Human and Long-Term Costs of Missed Diagnosis
When GDM goes undetected, women face increased risks of pregnancy complications including preeclampsia, larger infants, emergency cesarean sections, and stillbirth. Newborns born to mothers with undiagnosed GDM are more likely to require neonatal intensive care for breathing difficulties and low blood sugar.
The consequences extend beyond birth: mothers who had GDM have up to a 50% higher chance of developing type 2 diabetes within 5 to 10 years postpartum, and their children are at elevated lifelong risk of obesity and diabetes. These outcomes highlight the tangible human cost of diagnostic failures in maternity care.
Structural Inequality in Testing Practices
The UK relies on risk-factor-based screening rather than universal testing for GDM, unlike many other countries where all pregnant women are routinely screened. Additionally, in-clinic oral glucose tolerance tests (OGTTs), the current standard, face delays in blood sample processing that lower glucose concentration readings, resulting in false negatives and underdiagnosis.
Accurate diagnosis rates nearly double when blood samples are processed quickly and properly—from 9% to 22% in studied populations. This systemic issue disproportionately affects women from disadvantaged backgrounds, ethnic minorities, and those juggling childcare or work, further exacerbating health inequalities.
Innovations to Improve Accuracy and Equity
Innovative solutions such as at-home OGTT kits, which maintain clinical testing standards while eliminating delays in blood sample processing, have demonstrated success in identifying more GDM cases.
These technologies enhance accessibility by allowing women to test at home, reducing barriers like travel and fasting requirements. Early pilots with NHS Trusts show the approach improves diagnosis rates and equity, particularly among underserved populations.
Urgent Need for Policy Change
While more accurate testing may increase workload for maternity services, the cost of undiagnosed GDM is higher in terms of emergency interventions, neonatal care, and later-life chronic illnesses.
Recognizing underdiagnosis as a patient safety issue, guaranteeing reliable test results for all women, supporting innovative testing methods, and incorporating patient voices—especially from disadvantaged groups—are critical actions. Ensuring accurate, timely, and equitable testing is essential to improve maternal and child health outcomes nationwide.
Related topics
